CAMBRIDGE, Mass. — Blueprint Medicines Corporation announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYT is the first and only approved therapy for people living with ISM in Europe. Systemic mastocytosis...
Latest News
SAN DIEGO – Bluestar Genomics announces it received U.S. Food and Drug Administration (FDA) Breakthrough Device designation for its proprietary noninvasive pancreatic cancer detection test in patients with new-onset diabetes. The FDA’s Breakthrough Device program accelerates the development of medical devices that have the potential to effectively treat or diagnose...
Ingelheim am Rhein, Germany – Boehringer Ingelheim announced today that the FIBRONEER™-IPF trial met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] (FVC) at week 52 versus placebo. FVC is a measure of lung function.1 Based on these results, Boehringer Ingelheim will submit...
FORT WASHINGTON, Pennsylvania and INGELHEIM, Germany – Boehringer Ingelheim and Vitae Pharmaceuticals, Inc., announced today that they have entered into a significant worldwide collaboration to research and develop beta-secretase (BACE) inhibitors for the treatment of Alzheimer’s disease. Current therapies for Alzheimer’s disease can improve symptoms, but do not affect the...
Oxford, UK – Enara Bio today announced that Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using Enara Bio’s Dark Antigen discovery platform, EDAPT®. This licensing event is a major milestone in the strategic collaboration between the companies...
Ingelheim am Rhein, Germany – Boehringer Ingelheim on Wednesday announced a multi-target collaboration agreement with Chinese biotech Suzhou Ribo Life Science and its Swedish unit Ribocure Pharmaceuticals to develop siRNA-based treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis. The companies did not disclose what targets they would focus on, nor did...
VANCOUVER, Canada — Bold Therapeutics, a clinical-stage biopharmaceutical company developing novel metallotherapeutics, presented positive Phase 2 safety and efficacy data in advanced metastatic colorectal cancer (mCRC) patients treated with BOLD-100 in combination with FOLFOX previously treated with FOLFOX/CAPOX at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium on January...
PARKVILLE, Missouri— Bond Biosciences, Inc., a clinical-stage, privately held biopharmaceutical company today announced a successful meeting with the U.S. Food and Drug Administration (FDA) following a scheduled pre-IND meeting with the Office of Cardiology, Hematology, Endocrinology, and Nephrology, Division of Nonmalignant Hematology to seek advice on the BBI-001 development program...
Results of a retrospective analysis showed a significantly elevated risk of bone fractures in a population-based cohort of patients with myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV), compared with the overall population. These findings were published in Leukemia and Lymphoma. The Philadelphia chromosome-negative MPNs, characterized by clonal proliferation of 1 or more...
Melbourne, Australia – A drug that boosts bone growth in children with the most common form of dwarfism, may also reduce their chances of sudden infant death syndrome, sleep apnea and needing surgery, according to a new study. The international research trial, led by Murdoch Children’s Research Institute (MCRI) and...